Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
2.
Front Immunol ; 12: 796065, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-35003119

RESUMO

Rubella virus (RuV) has recently been found in association with granulomatous inflammation of the skin and several internal organs in patients with inborn errors of immunity (IEI). The cellular tropism and molecular mechanisms of RuV persistence and pathogenesis in select immunocompromised hosts are not clear. We provide clinical, immunological, virological, and histological data on a cohort of 28 patients with a broad spectrum of IEI and RuV-associated granulomas in skin and nine extracutaneous tissues to further delineate this relationship. Combined immunodeficiency was the most frequent diagnosis (67.8%) among patients. Patients with previously undocumented conditions, i.e., humoral immunodeficiencies, a secondary immunodeficiency, and a defect of innate immunity were identified as being susceptible to RuV-associated granulomas. Hematopoietic cell transplantation was the most successful treatment in this case series resulting in granuloma resolution; steroids, and TNF-α and IL-1R inhibitors were moderately effective. In addition to M2 macrophages, neutrophils were identified by immunohistochemical analysis as a novel cell type infected with RuV. Four patterns of RuV-associated granulomatous inflammation were classified based on the structural organization of granulomas and identity and location of cell types harboring RuV antigen. Identification of conditions that increase susceptibility to RuV-associated granulomas combined with structural characterization of the granulomas may lead to a better understanding of the pathogenesis of RuV-associated granulomas and discover new targets for therapeutic interventions.


Assuntos
Granuloma/imunologia , Inflamação/imunologia , Macrófagos/imunologia , Neutrófilos/imunologia , Vírus da Rubéola/fisiologia , Rubéola (Sarampo Alemão)/imunologia , Idoso , Antígenos Virais/metabolismo , Estudos de Coortes , Citocinas/metabolismo , Suscetibilidade a Doenças , Feminino , Doenças Genéticas Inatas , Transplante de Células-Tronco Hematopoéticas , Humanos , Imuno-Histoquímica , Síndromes de Imunodeficiência , Masculino , Pessoa de Meia-Idade , Receptores de Interleucina-1/antagonistas & inibidores , Rubéola (Sarampo Alemão)/complicações , Células Th2/imunologia , Fator de Necrose Tumoral alfa/antagonistas & inibidores
4.
Rheumatology (Oxford) ; 49(12): 2264-72, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20724433

RESUMO

OBJECTIVES: The contribution of IL-17-producing Th17 cells to the pathogenesis of T-cell-mediated inflammatory disorders such as RA and atopic dermatitis (AD) has to be viewed in relation to the role of Th1/Th2 cells and long-recognized key cytokines like TNF. We aimed to study the frequency and migration-associated phenotype of peripheral Th17, Th1 and Th2 cells in healthy individuals, RA and AD patients, and to study the influence of anti-TNF therapy in RA. METHODS: Intracellular IL-17, IFN-γ and IL-4 production and CC-chemokine receptor CCR4 and CCR6 expression were analysed flow cytometrically in peripheral memory Th cells from healthy individuals, AD and RA patients. The latter were grouped by disease activity and presence or absence of adalimumab therapy. In RA patients initiating anti-TNF therapy, cytokine production by in vitro-stimulated peripheral mononuclear cells was measured by cytometric bead array. RESULTS: The peripheral Th17 cell frequency is elevated in AD but not in RA. In RA, Th17 cells and IL-17 production increase after anti-TNF therapy, irrespective of disease activity. Th1 cells and IFN-γ production are elevated in remission and under anti-TNF therapy. CCR6 expression is up-regulated in Th17 cells, but RA patients in remission under anti-TNF therapy have significantly lower expression than those with active disease. CONCLUSIONS: The increase in peripheral Th17 cells in RA patients after anti-TNF therapy is accompanied by a decrease in Th17-specific CCR6 expression, which might prevent homing of these potentially pro-inflammatory cells to the synovium.


Assuntos
Artrite Reumatoide/imunologia , Quimiocinas/imunologia , Interleucina-17/biossíntese , Receptores de Quimiocinas/imunologia , Linfócitos T Auxiliares-Indutores/imunologia , Linfócitos T Auxiliares-Indutores/metabolismo , Inibidores do Fator de Necrose Tumoral , Adalimumab , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados , Artrite Reumatoide/tratamento farmacológico , Estudos de Casos e Controles , Quimiocinas/efeitos dos fármacos , Feminino , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Receptores de Quimiocinas/efeitos dos fármacos , Fatores de Necrose Tumoral/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA